Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL

NCT03259529 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Diffuse Large B Cell Lymphoma

Interventions

DRUG: Bendamustine hydrochloride
DRUG: Gemcitabine 500 mg
DRUG: Gemcitabine 700 mg
DRUG: Gemcitabine 1000 mg
DRUG: Nivolumab
DRUG: Rituximab

Sponsor

St. Petersburg State Pavlov Medical University